Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Clever Leaves Holdings's Price-to-Tangible-Book or its related term are showing as below:
CLVR's Price-to-Tangible-Book is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.26 * Ranked among companies with meaningful Price-to-Tangible-Book only.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Clever Leaves Holdings Price-to-Tangible-Book Related Terms
Clever Leaves Holdings Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Clever Leaves Holdings's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLVR vs CNNC, CLSH, PRFX: Price-to-Tangible-Book Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Clever Leaves Holdings's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clever Leaves Holdings Price-to-Tangible-Book vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Clever Leaves Holdings's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Clever Leaves Holdings's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Clever Leaves Holdings (CLVR) has a Price-to-Tangible-Book of 0.00 as of Sep. 15, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Clever Leaves Holdings and its competitors.
Is Clever Leaves Holdings' Price-to-Tangible-Book too high?
Clever Leaves Holdings' current Price-to-Tangible-Book is 0.00. Overall, Clever Leaves Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Clever Leaves Holdings' Price-to-Tangible-Book compare to CNNC and CLSH?
Clever Leaves Holdings' Price-to-Tangible-Book of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Price-to-Tangible-Book is 2.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Drug Manufacturers company?
The median Price-to-Tangible-Book among Drug Manufacturers companies is 2.26, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Clever Leaves Holdings and its competitors. For the Drug Manufacturers industry, the median Price-to-Tangible-Book is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clever Leaves Holdings's current Price-to-Tangible-Book is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clever Leaves Holdings stock overvalued right now?
Clever Leaves Holdings (CLVR) has a current Price-to-Tangible-Book of 0.00. The current Price-to-Tangible-Book is 0.00. Clever Leaves Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Clever Leaves Holdings (CLVR), the current Price-to-Tangible-Book is 0.00 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clever Leaves Holdings Inc is a producer of pharmaceutical and consumer cannabis brands. The company operates and has investments in Canada, Colombia, Germany, Portugal, and the United States. The company operates in two reportable segments namely, the Cannabinoid segment which is comprised of the company's cultivation, extraction, and commercialization of cannabinoid products; and the Non-Cannabinoid operating segment which generates maximum revenue and is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements.
12GF Score
Get the complete analysis for CLVR
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLVR has been successfully added to your 
